T. Rowe Price Associates
TLSI icon

T. Rowe Price Associates’s TriSalus Life Sciences TLSI Stock Holding History

T. Rowe Price Associates’s Portfolio TLSI Stock Details TLSI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$179K Buy
39,335
+18,041
+85% +$71.7K ﹤0.01% 3037
2026
Q1 		$86K Buy
21,294
+6,480
+44% +$31.7K ﹤0.01% 3026
2025
Q4 		$104K Buy
+14,814
New +$83K ﹤0.01% 2939

Other funds holding TLSI

FLAM
First Light Asset Management Edina, Minnesota $1.65B AUM 203.21% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Cerity Partners
Cerity Partners New York $82.7B AUM 28.53% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
GGHC
Gilder Gagnon Howe & Co New York $9.69B AUM 55.7% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
WPC
White Pine Capital Bloomington, Minnesota $423M AUM 67.01% 1-Year Est. Return
TSW
Thompson Siegel & Walmsley Richmond, Virginia $5.57B AUM 9.46% 1-Year Est. Return

T. Rowe Price Associates's TLSI Position: Q2 2026 in Review

T. Rowe Price Associates increased its TriSalus Life Sciences (TLSI) stake by 85% in Q2 2026, buying an estimated $71.7K and bringing the position to 39,335 shares worth $179K. The position accounts for ﹤0.01% of the portfolio, ranked #3037.

T. Rowe Price Associates first reported a position in TLSI in Q4 2025 and has held it in 3 quarters since. 78 funds tracked by Wall St. Rank hold TLSI as of Q2 2026.

  • T. Rowe Price Associates held 39,335 shares of TriSalus Life Sciences worth $179K as of Q2 2026.
  • T. Rowe Price Associates bought 18,041 TriSalus Life Sciences shares in Q2 2026, an estimated $71.7K.
  • TriSalus Life Sciences made up ﹤0.01% of T. Rowe Price Associates's portfolio in Q2 2026, its #3037 holding.
  • T. Rowe Price Associates first reported a position in TriSalus Life Sciences in Q4 2025 and has held it in 3 quarters since.
  • 78 funds tracked by Wall St. Rank held TriSalus Life Sciences as of Q2 2026.

Based on T. Rowe Price Associates's 13F filing for Q2 2026, filed 14 Aug 2026.